Loading...
Loading...
AIKI| Name | Value |
|---|---|
| Revenues | 963.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 963.0K |
| Operating Expense | 4,067.0K |
| Operating I/L | -3,104.0K |
| Other Income/Expense | -437.0K |
| Interest Income | 208.0K |
| Pretax | -3,541.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -3,541.0K |
AIkido Pharma Inc. is a biotechnology company specializing in the development of small-molecule anti-cancer therapeutics. Its pipeline includes treatments for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. The company is focused on developing DHA-dFdC, a pancreatic drug candidate, and KPC34, a small molecule treatment for AML and acute lymphoblastic leukemia. Additionally, AIkido Pharma is working on an antiviral platform targeting the replication of various viruses, including influenza virus, Ebolavirus, Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. The company generates revenue through the development and commercialization of its therapeutic and antiviral products.
